In conclusion, METTL3/m6A promotes gastric cancer growth and metastasis by facilitating pri-miR-17-92 processing into the oncogenic miRNA cluster and activating the AKT/mTOR pathway by targeting PTEN and TMEM127, which could be targeted by everolimus (Fig. 8f). The gene discussed is MTOR; the disease is gastric cancer.